<p>藍鳥公司（NASDAQ:BLBD - 獲取免費報告）週二的股價下跌了 8.5%。該公司的股價最低曾達到 68.05 美元，最後交易價格為 66.5450 美元。在午盤交易中，約有 30,194 股成交，較平均每日成交量 434,964 股下降了 93%。該股票此前收盤價為 72.74 美元。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>對於看漲投資者的三大高風險高回報投資</li>
</ul>
<p>多家券商最近對 BLBD 發佈了報告。Needham &amp; Company LLC 將藍鳥的目標價從 78.00 美元上調至 86.00 美元，並在 5 月 7 日的報告中給予該公司 “買入” 評級。巴克萊將藍鳥的目標價從 55.00 美元上調至 75.00 美元，並在 5 月 7 日的研究報告中給予該股票 “超配” 評級。華爾街 Zen 將藍鳥的股票評級從 “強烈買入” 下調至 “買入”，該報告於 2 月 7 日發佈。Freedom Capital 將藍鳥的股票評級從 “強烈買入” 下調至 “持有”，該研究報告於 5 月 7 日發佈。最後，BTIG Research 將藍鳥的股票目標價從 65.00 美元上調至 80.00 美元，並在 5 月 7 日的報告中給予該公司 “買入” 評級。六位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，藍鳥的平均評級為 “適度買入”，共識目標價為 75.80 美元。</p>
<p><strong>查看我們關於 BLBD 的最新股票報告</strong></p>
<h2>藍鳥股票表現</h2>
<ul>
<li>CRISPR Therapeutics 是基因編輯領域的 NVIDIA 嗎？</li>
</ul>
<p>該公司的 50 日移動平均線為 60.89 美元，200 日移動平均線為 55.32 美元。公司的速動比率為 1.27，流動比率為 1.83，債務與股本比率為 0.28。公司的市值為 20.5 億美元，市盈率為 15.86，市盈增長比率為 1.01，貝塔值為 1.38。</p>
<p>藍鳥（NASDAQ:BLBD - 獲取免費報告）最近在 5 月 6 日發佈了季度財報。該公司報告季度每股收益為 1.00 美元，超出市場共識預期的 0.88 美元，超出幅度為 0.12 美元。藍鳥的股本回報率為 53.68%，淨利潤率為 8.91%。該公司在本季度的收入為 3.5264 億美元，而分析師預期為 3.3523 億美元。在去年同期，該公司每股收益為 0.96 美元。藍鳥的收入同比下降了 1.7%。整體來看，研究分析師預測藍鳥公司在當前財政年度將發佈 4.35 美元的每股收益。</p>
<h2>藍鳥的內部交易</h2>
<ul>
<li>基因療法：為什麼單次治療要花費數百萬？</li>
</ul>
<p>在相關消息中，首席運營官 Jeffrey Scott Sanfrey 在 3 月 4 日的交易中出售了 5,192 股股票。股票的平均售價為 58.54 美元，總價值為 303,939.68 美元。出售完成後，首席運營官直接持有公司 39,011 股股票，價值約為 2,283,703.94 美元。這代表其持股比例下降了 11.75%。該交易已在 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，首席財務官 Razvan Radulescu 在 2 月 19 日的交易中出售了 3,925 股公司的股票。該股票的平均售價為 60.98 美元，總交易額為 239,346.50 美元。出售後，首席財務官持有公司 42,255 股股票，價值約為 2,576,709.90 美元。該交易使其持股比例下降了 8.50%。該交易的披露信息可在 SEC 文件中找到。公司內部人士持有公司股票的 1.10%。</p>
<h2>藍鳥的機構交易</h2>
<p>機構投資者和對沖基金最近調整了對該公司的持股。洛克菲勒資本管理公司在第四季度將其在藍鳥的持股增加了 210.0%。洛克菲勒資本管理公司現在擁有 775 股公司股票，價值 36,000 美元，此前在該期間內又購買了 525 股。Transamerica Financial Advisors LLC 在第四季度將其在藍鳥的持股增加了 222.7%。Transamerica Financial Advisors LLC 現在擁有 823 股公司股票，價值 39,000 美元，此前在該期間內又收購了 568 股。凱通國際資產管理有限公司在第三季度將其在藍鳥的持股增加了 10,028.6%。凱通國際資產管理有限公司現在擁有 709 股公司股票，價值 41,000 美元，此前在上個季度又收購了 702 股。Aster Capital Management DIFC Ltd 在第四季度購買了藍鳥的新頭寸，價值約為 41,000 美元。最後，Mcguire Capital Advisors Inc.在第四季度購買了藍鳥的新頭寸，價值約為 63,000 美元。目前 93.59% 的股票由機構投資者持有。</p>
<h2>關於藍鳥</h2>
<p>（獲取免費報告）</p>
<p>藍鳥公司（NASDAQ: BLBD）是一家領先的公交車和公共交通工具製造商，總部位於喬治亞州的福特谷。公司的核心業務包括設計、工程和生產校車和活動巴士，產品線包括常規（C 型）車型、公交風格（D 型）車型以及特殊需求和活動運輸的特殊配置。近年來，藍鳥擴大了其產品範圍，包括零排放電動校車，體現了其對先進推進技術和環境可持續性的承諾。</p>
<p>藍鳥成立於 1927 年，在學生交通運輸領域建立了安全和可靠的聲譽。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 Blue Bird</li>
<li>家得寶的拋售可能成為一個巨大的機會</li>
<li>五角大樓的人工智能轉型為國防股票注入動力</li>
<li>AAPL：忘掉 iPhone——服務將推動下一個增長階段</li>
<li>Ackman 和 Berkshire 在人工智能上相互對賭</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Blue Bird 嗎？</h2>
<p>在你考慮 Blue Bird 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Blue Bird 並不在名單上。</p>
<p>雖然 Blue Bird 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BLBD

<p>藍鳥公司（NASDAQ:BLBD）股價下跌 8.5%，至 66.54 美元，交易量較平均水平下降 93%。分析師對該公司的評級不一，目標股價範圍在 55 美元到 86 美元之間。公司報告每股收益為 1.00 美元，超出預期，但收入同比下降 1.7%。有內部人士出售股票的情況，並且機構投資者顯著增加了持股</p>

<p>Blue Bird Corporation (NASDAQ:BLBD - Get Free Report)'s share price was down 8.5% during trading on Tuesday . The company traded as low as $68.05 and last traded at $66.5450. Approximately 30,194 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 434,964 shares. The stock had previously closed at $72.74.</p>
<div class="lb-trans"><p>藍鳥公司（NASDAQ:BLBD - 獲取免費報告）週二的股價下跌了 8.5%。該公司的股價最低曾達到 68.05 美元，最後交易價格為 66.5450 美元。在午盤交易中，約有 30,194 股成交，較平均每日成交量 434,964 股下降了 93%。該股票此前收盤價為 72.74 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>Top 3 High-Risk, High-Reward Plays for Bullish Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>對於看漲投資者的三大高風險高回報投資</li>
</ul>
</div><p>A number of brokerages have recently issued reports on BLBD. Needham &amp; Company LLC upped their price target on Blue Bird from $78.00 to $86.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, May 7th. Barclays boosted their target price on Blue Bird from $55.00 to $75.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Blue Bird from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, February 7th. Freedom Capital lowered shares of Blue Bird from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, May 7th. Finally, BTIG Research boosted their price objective on shares of Blue Bird from $65.00 to $80.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Blue Bird has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $75.80.</p>
<div class="lb-trans"><p>多家券商最近對 BLBD 發佈了報告。Needham &amp; Company LLC 將藍鳥的目標價從 78.00 美元上調至 86.00 美元，並在 5 月 7 日的報告中給予該公司 “買入” 評級。巴克萊將藍鳥的目標價從 55.00 美元上調至 75.00 美元，並在 5 月 7 日的研究報告中給予該股票 “超配” 評級。華爾街 Zen 將藍鳥的股票評級從 “強烈買入” 下調至 “買入”，該報告於 2 月 7 日發佈。Freedom Capital 將藍鳥的股票評級從 “強烈買入” 下調至 “持有”，該研究報告於 5 月 7 日發佈。最後，BTIG Research 將藍鳥的股票目標價從 65.00 美元上調至 80.00 美元，並在 5 月 7 日的報告中給予該公司 “買入” 評級。六位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，藍鳥的平均評級為 “適度買入”，共識目標價為 75.80 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on BLBD</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 BLBD 的最新股票報告</strong></p>
</div><h2>Blue Bird Stock Performance</h2>
<div class="lb-trans"><h2>藍鳥股票表現</h2>
</div><ul>
<li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 是基因編輯領域的 NVIDIA 嗎？</li>
</ul>
</div><p>The business's fifty day moving average is $60.89 and its 200-day moving average is $55.32. The company has a quick ratio of 1.27, a current ratio of 1.83 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.05 billion, a PE ratio of 15.86, a P/E/G ratio of 1.01 and a beta of 1.38.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 60.89 美元，200 日移動平均線為 55.32 美元。公司的速動比率為 1.27，流動比率為 1.83，債務與股本比率為 0.28。公司的市值為 20.5 億美元，市盈率為 15.86，市盈增長比率為 1.01，貝塔值為 1.38。</p>
</div><p>Blue Bird (NASDAQ:BLBD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.88 by $0.12. Blue Bird had a return on equity of 53.68% and a net margin of 8.91%.The firm had revenue of $352.64 million during the quarter, compared to analyst estimates of $335.23 million. During the same period in the prior year, the business posted $0.96 EPS. Blue Bird's revenue was down 1.7% on a year-over-year basis. As a group, research analysts predict that Blue Bird Corporation will post 4.35 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>藍鳥（NASDAQ:BLBD - 獲取免費報告）最近在 5 月 6 日發佈了季度財報。該公司報告季度每股收益為 1.00 美元，超出市場共識預期的 0.88 美元，超出幅度為 0.12 美元。藍鳥的股本回報率為 53.68%，淨利潤率為 8.91%。該公司在本季度的收入為 3.5264 億美元，而分析師預期為 3.3523 億美元。在去年同期，該公司每股收益為 0.96 美元。藍鳥的收入同比下降了 1.7%。整體來看，研究分析師預測藍鳥公司在當前財政年度將發佈 4.35 美元的每股收益。</p>
</div><h2>Insider Transactions at Blue Bird</h2>
<div class="lb-trans"><h2>藍鳥的內部交易</h2>
</div><ul>
<li>Gene therapy: Why does it cost millions for a single treatment?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因療法：為什麼單次治療要花費數百萬？</li>
</ul>
</div><p>In related news, COO Jeffrey Scott Sanfrey sold 5,192 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $58.54, for a total value of $303,939.68. Following the completion of the sale, the chief operating officer directly owned 39,011 shares of the company's stock, valued at approximately $2,283,703.94. This represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Razvan Radulescu sold 3,925 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $60.98, for a total transaction of $239,346.50. Following the sale, the chief financial officer owned 42,255 shares in the company, valued at approximately $2,576,709.90. The trade was a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.10% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席運營官 Jeffrey Scott Sanfrey 在 3 月 4 日的交易中出售了 5,192 股股票。股票的平均售價為 58.54 美元，總價值為 303,939.68 美元。出售完成後，首席運營官直接持有公司 39,011 股股票，價值約為 2,283,703.94 美元。這代表其持股比例下降了 11.75%。該交易已在 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，首席財務官 Razvan Radulescu 在 2 月 19 日的交易中出售了 3,925 股公司的股票。該股票的平均售價為 60.98 美元，總交易額為 239,346.50 美元。出售後，首席財務官持有公司 42,255 股股票，價值約為 2,576,709.90 美元。該交易使其持股比例下降了 8.50%。該交易的披露信息可在 SEC 文件中找到。公司內部人士持有公司股票的 1.10%。</p>
</div><h2>Institutional Trading of Blue Bird</h2>
<div class="lb-trans"><h2>藍鳥的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Rockefeller Capital Management L.P. boosted its holdings in Blue Bird by 210.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 775 shares of the company's stock worth $36,000 after buying an additional 525 shares during the period. Transamerica Financial Advisors LLC raised its holdings in Blue Bird by 222.7% during the fourth quarter. Transamerica Financial Advisors LLC now owns 823 shares of the company's stock valued at $39,000 after acquiring an additional 568 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Blue Bird by 10,028.6% in the third quarter. Caitong International Asset Management Co. Ltd now owns 709 shares of the company's stock valued at $41,000 after acquiring an additional 702 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Blue Bird in the fourth quarter valued at about $41,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Blue Bird in the fourth quarter worth about $63,000. 93.59% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該公司的持股。洛克菲勒資本管理公司在第四季度將其在藍鳥的持股增加了 210.0%。洛克菲勒資本管理公司現在擁有 775 股公司股票，價值 36,000 美元，此前在該期間內又購買了 525 股。Transamerica Financial Advisors LLC 在第四季度將其在藍鳥的持股增加了 222.7%。Transamerica Financial Advisors LLC 現在擁有 823 股公司股票，價值 39,000 美元，此前在該期間內又收購了 568 股。凱通國際資產管理有限公司在第三季度將其在藍鳥的持股增加了 10,028.6%。凱通國際資產管理有限公司現在擁有 709 股公司股票，價值 41,000 美元，此前在上個季度又收購了 702 股。Aster Capital Management DIFC Ltd 在第四季度購買了藍鳥的新頭寸，價值約為 41,000 美元。最後，Mcguire Capital Advisors Inc.在第四季度購買了藍鳥的新頭寸，價值約為 63,000 美元。目前 93.59% 的股票由機構投資者持有。</p>
</div><h2>About Blue Bird</h2>
<div class="lb-trans"><h2>關於藍鳥</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Blue Bird Corporation NASDAQ: BLBD is a leading manufacturer of buses and mass transportation vehicles headquartered in Fort Valley, Georgia. The company's core business encompasses the design, engineering, and production of school buses and activity buses, with a product lineup that includes conventional (Type C) models, transit-style (Type D) models and specialty configurations for special-needs and activity transport. In recent years, Blue Bird has expanded its offerings to include zero-emission electric school buses, reflecting its commitment to advanced propulsion technologies and environmental sustainability.</p>
<div class="lb-trans"><p>藍鳥公司（NASDAQ: BLBD）是一家領先的公交車和公共交通工具製造商，總部位於喬治亞州的福特谷。公司的核心業務包括設計、工程和生產校車和活動巴士，產品線包括常規（C 型）車型、公交風格（D 型）車型以及特殊需求和活動運輸的特殊配置。近年來，藍鳥擴大了其產品範圍，包括零排放電動校車，體現了其對先進推進技術和環境可持續性的承諾。</p>
</div><p>Established in 1927, Blue Bird has built a legacy of safety and reliability in student transportation.</p>
<div class="lb-trans"><p>藍鳥成立於 1927 年，在學生交通運輸領域建立了安全和可靠的聲譽。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Blue Bird</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
<li>The Pentagon's AI Pivot Supercharges Defense Stocks</li>
<li>AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth</li>
<li>Ackman and Berkshire Are Betting Against Each Other on AI</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Blue Bird</li>
<li>家得寶的拋售可能成為一個巨大的機會</li>
<li>五角大樓的人工智能轉型為國防股票注入動力</li>
<li>AAPL：忘掉 iPhone——服務將推動下一個增長階段</li>
<li>Ackman 和 Berkshire 在人工智能上相互對賭</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Blue Bird Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Blue Bird 嗎？</h2>
</div><p>Before you consider Blue Bird, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Blue Bird 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blue Bird wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Blue Bird 並不在名單上。</p>
</div><p>While Blue Bird currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Blue Bird 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Blue Bird (NASDAQ:BLBD) 股價下跌 8.5% - 是否應該賣出？